NDA submitted for DM-1796 for postherpetic neuralgia (PHN) - ONA
Links shared publicly online about this topic.
- 1,274total visits
NDA submitted for DM-1796 for postherpetic neuralgia (PHN) - ONA
Depomed, Inc. announced that its licensee, Abbott Laboratories, has submitted a New Drug Application (NDA) for DM-1796 (extended-release gabapentin) to the FDA for the management of postherpetic neuralgia (PHN), or pain after shingles.
View full resource at oncologynurseadvisor.com
Tags: Migraine Prevention Medication, Seizure Medication, Drug, FDA, Neurontin, Abbott Laboratories, Epilepsy Medication
Most Recently Shared on March 31, 2010 at 8:46 pm By:
NDA submitted for DM-1796 for postherpetic neuralgia (PHN) http://goo.gl/fb/1sdMI
Depomed Announces Submission Of New Drug Application For Investigational Postherpetic Neuralgia Treatment DM-1796
medicalnewstoday.com — “Depomed, Inc. (NASDAQ: DEPO) announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic ne” View full resource at medicalnewstoday.com
Most Recently Shared on March 31, 2010 at 9:07 pm By:
Depomed Announces Submission Of New Drug Application For Investigational Postherpetic Neuralgia Treatment DM-1796 Dep.. http://bit.ly/9vmKHK
Advertisement
